Introduction
Anidulafungin, a semi-synthetic derivative of echinocandin B, has been developed and launched as an intravenous treatment for serious fungal infections, such as candidemia, Candida-derived peritonitis, intra-abdominal abscesses, and esophageal candidiasis. As a non-competitive inhibitor of 1,3-b-D-glucan synthase, which is responsible for the formation of glucan polymers, anidulafungin interferes with the cell wall synthesis of most pathogenic fungi. This mode of action is characteristic of the echinocandin class of antifungals. While the first member of this class, cilofungin, was withdrawn due to toxicity associated with the formulation vehicle, anidulafungin follows the successful introduction of caspofungin and micafungin. Compared to the other echinocandins, anidulafungin appears to be more potent (MIC90 ofr0.25 mg/mL for C.albicans, 0.5 mg/mL for C.glabrata, 1 mg/mL for C. krusel and C.tropicalis, 2mg/mL for C.lusitaniae, and 2 mg/mL for Aspergillus spp) and is devoid of significant drug interactions since it is neither an inhibitor nor substrate of the cytochrome P450 isoenzymes. The emergence of the echinocandins circumvents the concern regarding the rising resistance to the azole and amphotericin B antifungals; no cross-resistance is expected because the echinocandins work at the cell wall rather than the cell membrane.
API 99%Min Anidulafungin CAS 166663-25-8
| Product Name: |
Anidulafungin |
| Synonyms: |
Anidulafungin;Echinocandin B, 1-(4R,5R)-4,5-dihydroxy-N2-4-(pentyloxy)1,1:4,1-terphenyl-4-ylcarbonyl-L-ornithine-;Anidulafungin(LY303366);Ecalta;Eraxis;LY 303366;nidulafungin;Anidulafungin-d11 |
| CAS: |
166663-25-8 |
| MF: |
C58H73N7O17 |
| MW: |
1140.25 |
| EINECS: |
658-060-4 |
| Product Categories: |
Antifungals;API;Inhibitors |
| Molecular Structure: |
|
Uses
Anidulafungin is a semi-synthetic cyclic lipopeptide belonging to the echinocandin class that was reported in 1995 and commercially developed by Eli Lilly. Anidulafungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi and is extensively referenced in the literature with over 400 citations.Nucleoside reverse transcriptase inhibitor (NRTI) for HIV treatment in adults.
Function
For use in the treatment of Candidemia and certain invasive forms of candidosis Esophageal candidosis.
Packing & Shipment
Quality Control of Health Sources
1) A system in accordance with GMP standard, supervision on whole production process.
2) Health Sources is equipped with advanced detecting device, such as AFS, GC, HPLC, UV etc, supply the
Detailed Certificate of Analysis.
3) Procurement-Strictly on selecting raw materials.
4) Production-Strictly according to the standard specifications, conform to USP, EP, BP, CP, AJI, FCC etc
Pharmaceutical and/or food standards.
5) Warehousing and storage:Clear and dry condition with suitable temperature.
6) Transportation - Audit and supervise the logistics environment to ensure storage safety.
7) Keep samples for all batches goods to be traceable in case of quality discrepance.
Certification
Q1:Which kind of payment terms do you accept?
For small order,you can pay by T/T or Western Union ,nomal order by T/T to our company account.
Q2:Can you give me a discount price?
Surely,It depend on your quantity.
Q3:How can I get a sample?
Free samples is available,but freight charges will be at your account and the charges will be return to you or deduct from your order in the future.
Q4:How to confirm the Product Quality before placing orders?
You can get free samples for some products,you only need to pay the shipping cost or arrange a courier to us and take the samples.You can send us your product specifications and requests,we will manufacture the products according to your requests.
Q5:How do you treat quality complaint?
First of all, our quality control will reduce the quality problem to near zero.If there is a real quality problem caused by us, we will send you free goods for replacement or refund you
Audited Supplier 
Audited Supplier 
){kind=link}
){kind=link}